NCT05018416View on ClinicalTrials.gov

Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions
Chronic Kidney DiseasesType 1 Diabetes MellitusType 2 Diabetes Mellitus
Interventions
BIOLOGICAL

Renal Autologous Cell Therapy (REACT)

Autologous selected renal cells (SRC)

Trial Locations (5)

19713

Nephrology Associates, Newark

83687

Boise Kidney and Hypertension Institute - Frenova, Nampa

80210-5073

Kidney Associates of Colorado, P.C. - Frenova, Denver

49007-3889

Paragon Health, PC d/b/a Nephrology Center, PC - Frenova, Kalamazoo

38801-6560

Nephrology and Hypertension Associates Ltd - Frenova, Tupelo

Sponsors

Lead Sponsor

Prokidney
All Listed Sponsors
lead

Prokidney

INDUSTRY